Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2-5, 2018 in New Orleans, LA. The conference will address all levels of basic, population, clinical, and transdisciplinary research related to cancer and will bring together physicians, scientists, health professionals, and health care leaders working in a variety of disciplines to discuss the latest findings in their fields. Patient Advocates attending the meeting will communicate to scientists the key issues, questions, and concerns of the survivor and patient advocacy communities; and network with scientists and fellow advocates fr...
Attached is a letter to the editor of the Kidney Cancer Journal and editorial response regarding the use of checkpoint inhibitors in non-clear cell RCC. We’re grateful to the editors of the journal for graciously providing this update for patients with rare types of kidney cancer. KCJ letter
KCCure joins 239 advocacy organizations asking Congress and CMS to reconsider changes allowing Medicare Advantage plans to implement a new policy that could negatively impact Medicare patients with kidney cancer.
This is to notify the research community of the recently extended deadline for the Fiscal Year 2018 (FY18) funding opportunities for the Department of Defense (DOD) Kidney Cancer Research Program (KCRP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).
On September 7th, the Harvard Medical Research Centers including Dana Farber, Beth Isreal, Brigham & Women's will once again hold their annual Kidney Cancer Symposium at the Newton Massachessetts Marriott. The Symposium is an all-day in-person and virtual event beginning at 8:00 a.m. and concluding at 3:30 pm.
KCCure hits goal of raising $50,000 in new kidney cancer research funding. Learn more about our Kidney Cancer Research Grant Program and our mission for find a cure for kidney cancer.
July 30, 2018 Washington, DC, – The Kidney Cancer Research Alliance(KCCure) responded to the Committee for Medicinal Products for Human Use (CHMP) recommendation against approval by the European Medicines Agency (EMA) of ipilimumab (Yervoy) combined with nivolumab (Opdivo) for the first line treatment of high and intermediate risk metastatic renal cell carcinoma (kidney cancer). The question of single-agent versus combination therapy is relevant in kidney cancer today and we agree with CHMP that additional data showing the superiority of adding ipilimumab to nivolumab would benefit the field and broaden our understanding of how these agents work in kidney cancer. However, we don’t believe this question alone is sufficient enough to justify denying kidney cancer patients access to a treatme...
During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor). This is a controversial question and one that is being debated by many physicians. We want to include the patient voice in that debate. Please take a few minutes to fill out this brief survey to help us sharing the patient perspective at ASCO. As always, your personal data will not be sharing with anyone. Thank you for taking part!